inflammatory bowel disease

China Infrastructure Investment Corp. (Nasdaq: CIIC) 109.7% HIGHER; sky-rocketing today amid no news. Volume is already about 7x normal volume today.

Athersys, Inc. (Nasdaq: ATHX) 70.8% HIGHER; continuing sharply higher once again today following yesterday's news of an agreement with Pfizer to develop and commercialize investigational stem cell therapy MultiStem for the treatment of Inflammatory Bowel Disease.

The stock soared more than 140% yesterday.

Athersys, Inc. (Nasdaq: ATHX) 207% HIGHER; entered into an agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize MultiStem for the treatment of Inflammatory Bowel Disease. Click here to see the full report.

Compugen Ltd. (NASDAQ: CGEN) 45.5% HIGHER; announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease, a commonly used term covering ulcerative colitis and Crohn's disease. Click here for the full report.